Avinger, Inc. (NASDAQ:AVGR) Short Interest Update

Avinger, Inc. (NASDAQ:AVGR) was the target of a large decline in short interest in April. As of April 15th, there was short interest totalling 41,800 shares, a decline of 16.9% from the March 31st total of 50,300 shares. Approximately 2.9% of the shares of the stock are sold short. Based on an average daily trading volume, of 53,000 shares, the days-to-cover ratio is presently 0.8 days.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. StockNews.com initiated coverage on shares of Avinger in a research report on Wednesday. They set a “hold” rating for the company. HC Wainwright restated a “buy” rating and set a $5.00 target price on shares of Avinger in a research report on Thursday, March 21st.

Avinger Stock Down 5.1 %

Shares of AVGR stock traded down $0.20 during trading on Friday, hitting $3.73. The company had a trading volume of 6,045 shares, compared to its average volume of 17,030. The stock’s 50-day moving average is $3.47 and its two-hundred day moving average is $3.33. Avinger has a 52 week low of $2.50 and a 52 week high of $18.00.

Avinger (NASDAQ:AVGR) last posted its quarterly earnings data on Wednesday, March 20th. The medical device company reported ($3.93) earnings per share for the quarter, missing the consensus estimate of $0.64 by ($4.57). The firm had revenue of $1.91 million for the quarter, compared to analysts’ expectations of $2.52 million. Sell-side analysts predict that Avinger will post -2.08 EPS for the current fiscal year.

Avinger Company Profile

Avinger, Inc, a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.